
Christoph Correll

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/344910/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. Psychological Medicine, 2023, 53, 4064-4082.	4.5	9
2	Characteristics prior to and at time of diagnosis in pediatric bipolar disorder. Nordic Journal of Psychiatry, 2023, 77, 282-292.	1.3	0
3	Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study. CNS Spectrums, 2022, 27, 118-128.	1.2	11
4	Motor activity patterns can distinguish between interepisode bipolar disorder patients and healthy controls. CNS Spectrums, 2022, 27, 82-92.	1.2	9
5	Systematic identification and stratification of help-seeking school-aged youth with mental health problems: a novel approach to stage-based stepped-care. European Child and Adolescent Psychiatry, 2022, 31, 781-793.	4.7	5
6	Emotional abuse interacts with borderline personality in adolescent inpatients with binge-purging eating disorders. Eating and Weight Disorders, 2022, 27, 131-138.	2.5	5
7	Age at onset of mental disorders worldwide: large-scale meta-analysis ofÂ192 epidemiological studies. Molecular Psychiatry, 2022, 27, 281-295.	7.9	967
8	The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic. Journal of Affective Disorders, 2022, 299, 393-407.	4.1	22
9	Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study. Schizophrenia Bulletin, 2022, 48, 166-175.	4.3	26
10	Developing an International Standard Set of Patient-Reported Outcome Measures for Psychotic Disorders. Psychiatric Services, 2022, 73, 249-258.	2.0	13
11	Editorial Perspective: Challenges of research focusing on child and adolescent mental health during the COVIDâ€19 era: what studies are needed?. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2022, 63, 122-125.	5.2	12
12	Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data. Schizophrenia Bulletin, 2022, 48, 296-306.	4.3	21
13	Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review. European Neuropsychopharmacology, 2022, 54, 90-99.	0.7	5
14	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). Journal of Affective Disorders, 2022, 299, 367-376.	4.1	33
15	Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms. European Psychiatry, 2022, 65, 1-27.	0.2	10
16	Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study. Schizophrenia Research, 2022, 239, 83-91.	2.0	5
17	A largeâ€scale metaâ€analytic atlas of mental health problems prevalence during the COVIDâ€19 early pandemic. Journal of Medical Virology, 2022, 94, 1935-1949.	5.0	134
18	The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach. BMC Psychiatry, 2022, 22, 32.	2.6	11

#	Article	IF	CITATIONS
19	Risk factors of postpartum depression and depressive symptoms: umbrella review of current evidence from systematic reviews and meta-analyses of observational studies. British Journal of Psychiatry, 2022, 221, 591-602.	2.8	29
20	Early Antipsychotic Nonresponse as a Predictor of Nonresponse and Nonremission in Adolescents With Psychosis Treated With Aripiprazole or Quetiapine: Results From the TEA Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2022, , .	0.5	7
21	Long-term safety and effectiveness of open-label lurasidone in antipsychotic-NaÃ ⁻ ve versus previously treated adolescents with Schizophrenia: A post-hoc analysis. Schizophrenia Research, 2022, 240, 205-213.	2.0	3
22	Serious Adverse Drug Reactions in Children and Adolescents Treated On- and Off-Label with Antidepressants and Antipsychotics in Clinical Practice. Pharmacopsychiatry, 2022, 55, 255-265.	3.3	14
23	Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 201-219.	2.2	3
24	Lifetime prevalence and clinical correlates of nonsuicidal self-injury in youth inpatients with eating disorders: a retrospective chart review. Child and Adolescent Psychiatry and Mental Health, 2022, 16, 17.	2.5	7
25	Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. NPJ Schizophrenia, 2022, 8, 5.	3.6	48
26	The Impact of Inpatient Multimodal Treatment or Family-Based Treatment on Six-Month Weight Outcomes in Youth with Anorexia Nervosa: A Naturalistic, Cross-Continental Comparison. Nutrients, 2022, 14, 1396.	4.1	2
27	Reliability and Validity of the Bipolar Prodrome Symptom Interview and Scale-Full Prospective in Its Turkish Translation. Journal of Child and Adolescent Psychopharmacology, 2022, 32, 178-186.	1.3	5
28	Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study. Lancet Psychiatry,the, 2022, 9, 271-279.	7.4	25
29	An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 537-540.	3.2	6
30	Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. Lancet Psychiatry,the, 2022, 9, 291-306.	7.4	6
31	Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends. Neuroscience and Biobehavioral Reviews, 2022, 136, 104608.	6.1	67
32	Therapeutic drug monitoring of sertraline in children and adolescents: A naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorder. Comprehensive Psychiatry, 2022, 115, 152301.	3.1	13
33	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	3.3	107
34	Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia. Schizophrenia Bulletin, 2022, 48, 774-784.	4.3	9
35	Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naÃ ⁻ ve versus previously treated adolescents with an acute exacerbation of schizophrenia. European Psychiatry, 2022, 65, 1-35.	0.2	4
36	Temporal trends in associations between severe mental illness and risk of cardiovascular disease: A systematic review and meta-analysis. PLoS Medicine, 2022, 19, e1003960.	8.4	43

#	Article	IF	CITATIONS
37	Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis. Frontiers in Psychiatry, 2022, 13, 795866.	2.6	8
38	Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review. Molecular Psychiatry, 2022, 27, 3510-3519.	7.9	29
39	Mortality in people with schizophrenia: a systematic review and metaâ€analysis of relative risk and aggravating or attenuating factors. World Psychiatry, 2022, 21, 248-271.	10.4	156
40	Outcomes of a Standardized, High-Caloric, Inpatient Re-Alimentation Treatment Protocol in 120 Severely Malnourished Adolescents with Anorexia Nervosa. Journal of Clinical Medicine, 2022, 11, 2585.	2.4	6
41	Oral and longâ€ecting antipsychotics for relapse prevention in schizophreniaâ€spectrum disorders: a network metaâ€enalysis of 92 randomized trials including 22,645 participants. World Psychiatry, 2022, 21, 295-307.	10.4	44
42	The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations. European Neuropsychopharmacology, 2022, 59, 45-55.	0.7	7
43	Randomized controlled trial of cognitive remediation therapy in adolescent inpatients with anorexia nervosa: Neuropsychological outcomes. European Eating Disorders Review, 2022, 30, 772-786.	4.1	5
44	Drug–drug interactions involving antipsychotics and antihypertensives. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 285-298.	3.3	4
45	Outcomes During and After Early Intervention Services for First-Episode Psychosis: Results Over 5 Years From the RAISE-ETP Site-Randomized Trial. Schizophrenia Bulletin, 2022, 48, 1021-1031.	4.3	7
46	Age dependency of body mass index distribution in childhood and adolescent inpatients with anorexia nervosa with a focus on DSM-5 and ICD-11 weight criteria and severity specifiers. European Child and Adolescent Psychiatry, 2021, 30, 1081-1094.	4.7	12
47	Differential effects of age at illness onset on verbal memory functions in antipsychotic-naÃ⁻ve schizophrenia patients aged 12–43 years. Psychological Medicine, 2021, 51, 1570-1580.	4.5	17
48	The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. CNS Spectrums, 2021, 26, 562-586.	1.2	13
49	Oxidative stress parameters and antioxidants in patients with bipolar disorder: Results from a metaâ€analysis comparing patients, including stratification by polarity and euthymic status, with healthy controls. Bipolar Disorders, 2021, 23, 117-129.	1.9	53
50	Practice-Based Evidence and Clinical Guidance to Support Accelerated Re-Nutrition of Patients With Anorexia Nervosa. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 555-561.	0.5	19
51	Annual Research Review: Prevention of psychosis in adolescents – systematic review and metaâ€analysis of advances in detection, prognosis and intervention. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2021, 62, 657-673.	5.2	95
52	What is the Best Latent Structure of Negative Symptoms in Schizophrenia? A Systematic Review. Schizophrenia Bulletin Open, 2021, 2, sgab013.	1.7	8
53	Risk and protective factors for mental disorders with onset in childhood/adolescence: An umbrella review of published meta-analyses of observational longitudinal studies. Neuroscience and Biobehavioral Reviews, 2021, 120, 565-573.	6.1	14
54	Mortality After the First Diagnosis of Schizophrenia-Spectrum Disorders: A Population-based Retrospective Cohort Study. Schizophrenia Bulletin, 2021, 47, 864-874.	4.3	21

#	Article	IF	CITATIONS
55	Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2021, 47, 948-958.	4.3	26
56	Clinical validation of the Symptom Self-rating Scale for Schizophrenia (4S) among inpatients. Nordic Journal of Psychiatry, 2021, 75, 454-464.	1.3	5
57	Safety and tolerability of lumateperone 42Âmg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. Schizophrenia Research, 2021, 228, 198-205.	2.0	16
58	Standardized training in the rating of the six-item Positive And Negative Syndrome Scale (PANSS-6). Schizophrenia Research, 2021, 228, 438-446.	2.0	2
59	Effectiveness of Transdiagnostic Cognitive-Behavioral Psychotherapy Compared With Management as Usual for Youth With Common Mental Health Problems. JAMA Psychiatry, 2021, 78, 250.	11.0	28
60	Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview. Journal of Psychopharmacology, 2021, 35, 1081-1090.	4.0	9
61	Cardiometabolic Safety of Lumateperone (ITIâ^007): Post Hoc Analyses of Short-Term Randomized Trials and an Open-Label Long-Term Study in Schizophrenia. CNS Spectrums, 2021, 26, 152-152.	1.2	1
62	How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. Revista Brasileira De Psiquiatria, 2021, 43, 189-202.	1.7	32
63	How to Estimate QT Interval in Patients With Left or Right Bundle Branch Block. Journal of Clinical Psychopharmacology, 2021, 41, 323-326.	1.4	3
64	Safety and Effectiveness of SEPâ^'363856 in Schizophrenia: Results of a 6-Month, Open-Label Extension Study. CNS Spectrums, 2021, 26, 148-149.	1.2	12
65	Systematic review of transdermal treatment options in attention-deficit/hyperactivity disorder: implications for use in adult patients. CNS Spectrums, 2021, , 1-13.	1.2	0
66	Efficacy of Lurasidone in Antipsychotic-Naive vs. Antipsychotic-Exposed Adolescents with Schizophrenia: Post-Hoc Analysis of a Two-Year, Open-Label Study. CNS Spectrums, 2021, 26, 147-147.	1.2	2
67	Occurrence and accuracy of a register-based diagnosis of pediatric bipolar disorder: A nationwide cohort study. Australian and New Zealand Journal of Psychiatry, 2021, 55, 1101-1108.	2.3	1
68	Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. Lancet Psychiatry,the, 2021, 8, 387-404.	7.4	160
69	Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis. American Journal of Psychiatry, 2021, 178, 424-436.	7.2	54
70	Association of Low-Dose Quetiapine and Diabetes. JAMA Network Open, 2021, 4, e213209.	5.9	14
71	Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort. Schizophrenia Bulletin, 2021, 47, 1621-1630.	4.3	24
72	Development of a Symptom-Focused Model to Guide the Prescribing of Antipsychotics in Children and Adolescents: Results of the First Phase of the Safer and Targeted Use of Antipsychotics (SUAY) Clinical Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, , .	0.5	6

#	Article	IF	CITATIONS
73	Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia. JAMA Psychiatry, 2021, 78, 510.	11.0	63
74	Preventive psychiatry: a blueprint for improving the mental health of young people. World Psychiatry, 2021, 20, 200-221.	10.4	183
75	Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry, 2021, 20, 244-275.	10.4	76
76	Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials. Lancet Psychiatry,the, 2021, 8, 471-486.	7.4	36
77	Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort. Translational Psychiatry, 2021, 11, 360.	4.8	8
78	Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis. EClinicalMedicine, 2021, 36, 100909.	7.1	25
79	Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study. Schizophrenia Bulletin, 2021, 47, 1611-1620.	4.3	33
80	Dietary Consumption Among Youth with Antipsychotic-Induced Weight Gain and Changes Following Healthy Lifestyle Education. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 364-375.	1.3	4
81	Long-acting injectable versus oral antipsychotics for schizophrenia – Authors' reply. Lancet Psychiatry,the, 2021, 8, 567.	7.4	2
82	Impact of Lurasidone and Other Antipsychotics on Body Weight: Real-World, Retrospective, Comparative Study of 15,323 Adults with Schizophrenia. International Journal of General Medicine, 2021, Volume 14, 4081-4094.	1.8	4
83	Early detection of bipolar disorders and treatment recommendations for help-seeking adolescents and young adults: Findings of the Early Detection and Intervention Center Dresden. International Journal of Bipolar Disorders, 2021, 9, 23.	2.2	3
84	Identifying strategies to improve PANSS based dimensional models in schizophrenia: Accounting for multilevel structure, Bayesian model and clinical staging. Schizophrenia Research, 2021, , .	2.0	4
85	Discrepancies between staff and gold standard ratings of schizophrenia symptom severity. Psychiatry Research, 2021, 301, 113963.	3.3	1
86	Validity of the Aktibipo Self-rating Questionnaire for the Digital Self-assessment of Mood and Relapse Detection in Patients With Bipolar Disorder: Instrument Validation Study. JMIR Mental Health, 2021, 8, e26348.	3.3	0
87	Long-acting antipsychotics: is what we know really so? – Authors' reply. Lancet Psychiatry,the, 2021, 8, 651-652.	7.4	0
88	Measurement-based Diagnosis and Treatment for Tardive Dyskinesia. Journal of Clinical Psychiatry, 2021, 82, .	2.2	2
89	A systematic review and pooled, patientâ€level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica, 2021, 144, 329-341.	4.5	27
90	Huntington's Disease With Psychotic Features. primary care companion for CNS disorders, The, 2021, 23, .	0.6	1

#	Article	IF	CITATIONS
91	Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis. NPJ Schizophrenia, 2021, 7, 41.	3.6	6
92	Risk and protective factors for mental disorders beyond genetics: an evidenceâ€based atlas. World Psychiatry, 2021, 20, 417-436.	10.4	127
93	Individuals at increased risk for development of bipolar disorder display structural alterations similar to people with manifest disease. Translational Psychiatry, 2021, 11, 485.	4.8	13
94	Withdrawal-associated relapse is a potential source of bias – Authors' reply. Lancet Psychiatry,the, 2021, 8, 748-749.	7.4	0
95	Disparities in Screening and Treatment of Cardiovascular Diseases in Patients With Mental Disorders Across the World: Systematic Review and Meta-Analysis of 47 Observational Studies. American Journal of Psychiatry, 2021, 178, 793-803.	7.2	50
96	Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry,the, 2021, 8, 883-891.	7.4	50
97	Primary prevention of depression: An umbrella review of controlled interventions. Journal of Affective Disorders, 2021, 294, 957-970.	4.1	23
98	Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. CNS Drugs, 2021, 35, 39-59.	5.9	67
99	Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. Schizophrenia Bulletin, 2021, 47, 986-996.	4.3	9
100	What are the physical and mental health implications of duration of untreated psychosis?. European Psychiatry, 2021, 64, e46.	0.2	3
101	Longitudinal Course of Depressive, Anxiety, and Posttraumatic Stress Disorder Symptoms After Heart Surgery: A Meta-Analysis of 94 Studies. Psychosomatic Medicine, 2021, 83, 85-93.	2.0	15
102	Appraising the effectiveness of electrical and magnetic brain stimulation techniques in acute major depressive episodes: an umbrella review of meta-analyses of randomized controlled trials. Revista Brasileira De Psiquiatria, 2021, 43, 514-524.	1.7	15
103	Symptoms and Characteristics of Youth Hospitalized for Depression: Subthreshold Manic Symptoms Can Help Differentiate Bipolar from Unipolar Depression. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 545-552.	1.3	5
104	Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. CNS Drugs, 2021, 35, 1189-1205.	5.9	32
105	Diagnostic and Treatment Fundamentals for Tardive Dyskinesia. Journal of Clinical Psychiatry, 2021, 82,	2.2	1
106	CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12–17 Years, With First Episode Psychosis. Journal of Clinical Psychopharmacology, 2021, 41, 667-672.	1.4	2
107	Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia. JAMA Psychiatry, 2021, , .	11.0	4
108	Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPJ Schizophrenia, 2021, 7, 63.	3.6	39

#	Article	IF	CITATIONS
109	Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review. Frontiers in Psychiatry, 2021, 12, 808002.	2.6	14
110	Reasons for admission and variance of body weight at referral in female inpatients with anorexia nervosa in Germany. Child and Adolescent Psychiatry and Mental Health, 2021, 15, 78.	2.5	4
111	Network analysis of the relationship between depressive symptoms, demographics, nutrition, quality of life and medical condition factors in the Osteoarthritis Initiative database cohort of elderly North-American adults with or at risk for osteoarthritis. Epidemiology and Psychiatric Sciences, 2020, 29. e14.	3.9	20
112	Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. Psychological Medicine, 2020, 50, 1356-1367.	4.5	26
113	Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status. European Journal of Clinical Pharmacology, 2020, 76, 41-49.	1.9	13
114	Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study. Schizophrenia Research, 2020, 215, 408-415.	2.0	31
115	A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 83-94.	3.2	4
116	Ranking Antipsychotics for Efficacy and Safety in Schizophrenia. JAMA Psychiatry, 2020, 77, 225.	11.0	14
117	Incontinence and constipation in adolescent patients with anorexia nervosa—Results of a multicenter study from a German webâ€based registry for children and adolescents with anorexia nervosa. International Journal of Eating Disorders, 2020, 53, 219-228.	4.0	14
118	20â€year followâ€up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry, 2020, 19, 61-68.	10.4	232
119	The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophrenia, 2020, 6, 1.	3.6	193
120	Measuring movements in adolescents with psychosis using the Microsoft Kinect sensor: a pilot study exploring a new tool for assessing aspects of antipsychoticâ€induced parkinsonism. Child and Adolescent Mental Health, 2020, 25, 79-94.	3.5	0
121	Efficacy and Safety of Lumateperone for Treatment of Schizophrenia. JAMA Psychiatry, 2020, 77, 349.	11.0	226
122	Metformin addâ€on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry, 2020, 19, 69-80.	10.4	68
123	Metabolic Monitoring Rates of Youth Treated with Second-Generation Antipsychotics in Usual Care: Results of a Large US National Commercial Health Plan. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 119-122.	1.3	15
124	Better care for less money: costâ€effectiveness of integrated care in multiâ€episode patients with severeÂpsychosis. Acta Psychiatrica Scandinavica, 2020, 141, 221-230.	4.5	9
125	Rare copy number variants in individuals at clinical high risk for psychosis: Enrichment of synaptic/brainâ€related functional pathways. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2020, 183, 140-151.	1.7	0
126	Predictors of psychosis breakthrough during 24Âmonths of long-acting antipsychotic maintenance treatment in first episode schizophrenia. Schizophrenia Research, 2020, 225, 55-62.	2.0	23

#	Article	IF	CITATIONS
127	Most recommended medical interventions reach P < 0.005 for their primary outcomes in meta-analyses. International Journal of Epidemiology, 2020, 49, 885-893.	1.9	10
128	Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4â€^717â€^839 people. Lancet Psychiatry,the, 2020, 7, 52-63.	7.4	109
129	What is good mental health? A scoping review. European Neuropsychopharmacology, 2020, 31, 33-46.	0.7	131
130	M205. LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC EFFECTS IN A 1-YEAR STUDY. Schizophrenia Bulletin, 2020, 46, S214-S214.	4.3	3
131	Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients. Schizophrenia Bulletin Open, 2020, 1, .	1.7	3
132	Medical management of eating disorders: an update. Current Opinion in Psychiatry, 2020, 33, 542-553.	6.3	31
133	Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. Lancet Psychiatry,the, 2020, 7, 749-761.	7.4	66
134	How mental health care should change as a consequence of the COVID-19 pandemic. Lancet Psychiatry,the, 2020, 7, 813-824.	7.4	1,101
135	Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. BMC Medicine, 2020, 18, 215.	5.5	52
136	DSM-5 Attenuated Psychosis Syndrome in Adolescents Hospitalized With Non-psychotic Psychiatric Disorders. Frontiers in Psychiatry, 2020, 11, 568982.	2.6	7
137	Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism and Related Disorders, 2020, 77, 141-145.	2.2	4
138	Universal and selective interventions to promote good mental health in young people: Systematic review and meta-analysis. European Neuropsychopharmacology, 2020, 41, 28-39.	0.7	56
139	Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532094270.	2.7	21
140	Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. American Journal of Psychiatry, 2020, 177, 1168-1178.	7.2	72
141	Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics. Drugs, 2020, 80, 1763-1781.	10.9	39
142	Association between mental disorders and somatic conditions: protocol for an umbrella review. Evidence-Based Mental Health, 2020, 23, 135-139.	4.5	16
143	Consensus statement on the use of clozapine during the COVID-19 pandemic. Journal of Psychiatry and Neuroscience, 2020, 45, 222-223.	2.4	102
144	Adapting to the impact of COVID-19 on mental health: an international perspective. Journal of Psychiatry and Neuroscience, 2020, 45, 229-233.	2.4	8

#	Article	IF	CITATIONS
145	Clozapine and COVID-19: The authors respond. Journal of Psychiatry and Neuroscience, 2020, 45, E1-E2.	2.4	1
146	Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia —Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. Schizophrenia Bulletin, 2020, 46, 1459-1470.	4.3	58
147	The Importance of Second-Generation Antipsychotic-Related Weight Gain and Adherence Barriers in Youth with Bipolar Disorders: Patient, Parent, and Provider Perspectives. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 376-380.	1.3	16
148	Safety of 80 antidepressants, antipsychotics, antiâ€attentionâ€deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic metaâ€review of 78 adverse effects. World Psychiatry, 2020, 19, 214-232.	10.4	167
149	Current and Novel Approaches to Mitigate Cardiometabolic Adverse Effects of Second-Generation Antipsychotics. International Journal of Neuropsychopharmacology, 2020, 23, 491-495.	2.1	3
150	Efficacy of cognitiveâ€behavioral group therapy in patients at risk for serious mental illness presenting with subthreshold bipolar symptoms: Results from a prespecified interim analysis of a multicenter, randomized, controlled study. Bipolar Disorders, 2020, 22, 517-529.	1.9	14
151	Prevention of Psychosis. JAMA Psychiatry, 2020, 77, 755.	11.0	287
152	Assessment of Physical Activity Patterns in Adolescent Patients with Anorexia Nervosa and Their Effect on Weight Gain. Journal of Clinical Medicine, 2020, 9, 727.	2.4	5
153	Management of Patients With Severe Mental Illness During the Coronavirus Disease 2019 Pandemic. JAMA Psychiatry, 2020, 77, 977.	11.0	53
154	Psychological and nutritional correlates of objectively assessed physical activity in patients with anorexia nervosa. European Eating Disorders Review, 2020, 28, 559-570.	4.1	6
155	The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index. BMC Psychiatry, 2020, 20, 77.	2.6	14
156	<p>Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 519-534.	2.2	339
157	Demographic and Clinical Characteristics, Including Subsyndromal Symptoms Across Bipolar-Spectrum Disorders in Adolescents. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 222-234.	1.3	8
158	A symptom combination predicting treatment-resistant schizophrenia – A strategy for real-world clinical practice. Schizophrenia Research, 2020, 218, 195-200.	2.0	16
159	Frequency and Correlates of Acute Dystonic Reactions After Antipsychotic Initiation in 441 Children and Adolescents. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 366-375.	1.3	3
160	Cultural Influences in Psychiatry—Reply. JAMA - Journal of the American Medical Association, 2020, 323, 1193.	7.4	0
161	100 Olanzapine/Samidorphan for Schizophrenia: Weight Gain and Metabolic Outcomes in Phase 3 ENLIGHTEN-2 and Subsequent Long-Term, Open-Label Safety Study. CNS Spectrums, 2020, 25, 265-265.	1.2	1
162	104 Long-term Efficacy of Lurasidone in Antipsychotic-naÃ ⁻ ve vs. Antipsychotic-exposed Adolescents with Schizophrenia: Analysis of a Two-Year Study. CNS Spectrums, 2020, 25, 267-268.	1.2	0

#	Article	IF	CITATIONS
163	Long-term outcome of early-onset compared to adult-onset schizophrenia: A nationwide Danish register study. Schizophrenia Research, 2020, 220, 123-129.	2.0	11
164	Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use. Schizophrenia Bulletin, 2020, 46, 1547-1557.	4.3	17
165	Exploring Movement Impairments in Patients With Parkinson's Disease Using the Microsoft Kinect Sensor: A Feasibility Study. Frontiers in Neurology, 2020, 11, 610614.	2.4	5
166	Iron homeostasis alterations and risk for akathisia in patients treated with antipsychotics: A systematic review and meta-analysis of cross-sectional studies. European Neuropsychopharmacology, 2020, 35, 1-11.	0.7	12
167	The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. Focus (American Psychiatric Publishing), 2020, 18, 456-465.	0.8	8
168	Improving early recognition and intervention in people at increased risk for the development of bipolar disorder: study protocol of a prospective-longitudinal, naturalistic cohort study (Early-BipoLife). International Journal of Bipolar Disorders, 2020, 8, 22.	2.2	18
169	Diagnostic stability in children and adolescents with bipolar disorder, a nationwide register-based study. International Journal of Bipolar Disorders, 2020, 8, 14.	2.2	3
170	Outcomes of an Accelerated Inpatient Refeeding Protocol in 103 Extremely Underweight Adults with Anorexia Nervosa at a Specialized Clinic in Prien, Germany. Journal of Clinical Medicine, 2020, 9, 1535.	2.4	17
171	Antipsychotic Polypharmacy in Schizophrenia. Journal of Clinical Psychiatry, 2020, 81, .	2.2	16
172	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. Journal of Clinical Psychiatry, 2020, 81, .	2.2	86
173	Using Long-acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia. Journal of Clinical Psychiatry, 2020, 81, .	2.2	21
174	Current Treatment Options and Emerging Agents for Schizophrenia. Journal of Clinical Psychiatry, 2020, 81, .	2.2	15
175	Using Patient-Centered Assessment in Schizophrenia Care. Journal of Clinical Psychiatry, 2020, 81, .	2.2	16
176	Drs Kane and Correll Reply. Journal of Clinical Psychiatry, 2020, 81, .	2.2	0
177	Suicidality in Childhood and Adolescence. Deutsches Ärzteblatt International, 2020, 117, 261-267.	0.9	24
178	Cariprazine in the management of negative symptoms of schizophrenia: stateÂofÂtheÂart and future perspectives. Future Neurology, 2020, 15, .	0.5	7
179	Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics. JAMA Psychiatry, 2019, 76, 1052.	11.0	243
180	The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry,the, 2019, 6, 675-712.	7.4	815

#	Article	IF	CITATIONS
181	Antipsychotic use and risk of lifeâ€ŧhreatening medical events: umbrella review of observational studies. Acta Psychiatrica Scandinavica, 2019, 140, 227-243.	4.5	59
182	European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP). European Neuropsychopharmacology, 2019, 29, 1301-1311.	0.7	38
183	Clinical Characteristics of Inpatients with Childhood vs. Adolescent Anorexia Nervosa. Nutrients, 2019, 11, 2593.	4.1	27
184	Is Transcultural Psychiatry Possible?. JAMA - Journal of the American Medical Association, 2019, 322, 2167.	7.4	18
185	Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists. BMC Psychiatry, 2019, 19, 362.	2.6	35
186	An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder. Bipolar Disorders, 2019, 21, 720-740.	1.9	71
187	O12.1. CARDIOMETABOLIC ADVERSE EFFECTS AND ITS PREDICTORS IN CHILDREN AND ADOLESCENTS WITH FIRST-EPISODE PSYCHOSIS DURING TREATMENT WITH QUETIAPINE-ER VERSUS ARIPIPRAZOLE: 12-WEEK RESULTS: FROM THE TEA TRIAL. Schizophrenia Bulletin, 2019, 45, S197-S197.	4.3	0
188	Mullerian inhibiting substance, sex hormone binding globulin and sex hormone levels in stimulant-naÃ ⁻ ve, first-diagnosed prepubertal boys with attention-deficit/hyperactivity disorder: comparison with matched healthy controls as well as before and after oros-methylpenidate treatment. International Journal of Psychiatry in Clinical Practice, 2019, 23, 251-257.	2.4	4
189	Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectrums, 2019, 24, 38-69.	1.2	87
190	An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. Journal of Psychopharmacology, 2019, 33, 1227-1236.	4.0	24
191	Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study. PLoS ONE, 2019, 14, e0210674.	2.5	2
192	Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2537-2550.	2.2	20
193	Lifestyle Interventions for Weight Management in People with Serious Mental Illness: A Systematic Review with Meta-Analysis, Trial Sequential Analysis, and Meta-Regression Analysis Exploring the Mediators and Moderators of Treatment Effects. Psychotherapy and Psychosomatics, 2019, 88, 350-362.	8.8	60
194	Association of Antidepressant Use With Adverse Health Outcomes. JAMA Psychiatry, 2019, 76, 1241.	11.0	143
195	Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it) Tj ETQq1 1 0.78	4314 rg₿1 4.5	「/Overlock]
196	Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. Movement Disorders, 2019, 34, 1203-1209.	3.9	18
197	<p>Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1365-1379.	2.2	28
198	Longâ€term effectiveness of oral secondâ€generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and metaâ€analysis of direct headâ€toâ€head comparisons. World Psychiatry, 2019, 18, 208-224.	10.4	93

#	Article	IF	CITATIONS
199	Longitudinal outcomes in pediatric―and adultâ€onset bipolar patients compared to healthy and schizophrenia controls. Bipolar Disorders, 2019, 21, 514-524.	1.9	7
200	Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, 1062-1078.	0.5	16
201	84 Assessment of Current Clinical Practices in Recognizing and Treating Bipolar Disorder. CNS Spectrums, 2019, 24, 217-218.	1.2	Ο
202	Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. European Journal of Clinical Pharmacology, 2019, 75, 1109-1116.	1.9	8
203	Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study. Psychiatry Research, 2019, 274, 176-181.	3.3	8
204	Rates and predictors of one-year antipsychotic treatment discontinuation in first-episode schizophrenia: Results from an open-label, randomized, "real world―clinical trial. Psychiatry Research, 2019, 273, 631-640.	3.3	11
205	Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA Psychiatry, 2019, 76, 499.	11.0	191
206	Bipolar Prodrome Symptom Scale - Abbreviated Screen for Patients: Description and validation. Journal of Affective Disorders, 2019, 249, 357-365.	4.1	17
207	Patches. Journal of Clinical Psychiatry, 2019, 80, .	2.2	24
208	Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia. Journal of Clinical Psychiatry, 2019, 80, .	2.2	15
209	Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. Journal of Clinical Psychiatry, 2019, 80, .	2.2	157
210	Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019. Current Psychiatry Reports, 2019, 21, 124.	4.5	16
211	Glucagonâ€like peptideâ€1 receptor agonists for antipsychoticâ€associated cardioâ€metabolic risk factors: A systematic review and individual participant data metaâ€analysis. Diabetes, Obesity and Metabolism, 2019, 21, 293-302.	4.4	69
212	Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder. CNS Spectrums, 2019, 24, 479-495.	1.2	17
213	High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. CNS Spectrums, 2019, 24, 441-452.	1.2	15
214	Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics. CNS Spectrums, 2019, 24, 354-370.	1.2	17
215	Oneâ€year followâ€up on liraglutide treatment for prediabetes and overweight/obesity in clozapine―or olanzapineâ€treated patients. Acta Psychiatrica Scandinavica, 2019, 139, 26-36.	4.5	30
216	Creativity in persons atâ€risk for bipolar disorder—A pilot study. Microbial Biotechnology, 2019, 13, 1165-1172.	1.7	10

#	Article	IF	CITATIONS
217	Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study. CNS Spectrums, 2019, 24, 507-517.	1.2	12
218	Rhythmic low-field magnetic stimulation may improve depression by increasing brain-derived neurotrophic factor. CNS Spectrums, 2019, 24, 313-321.	1.2	11
219	Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1–12.5 Years. Schizophrenia Bulletin, 2019, 45, 315-329.	4.3	141
220	Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics). Journal of Clinical Psychiatry, 2019, 80, .	2.2	35
221	A simulations approach for meta-analysis of genetic association studies based on additive genetic model. Meta Gene, 2018, 16, 143-164.	0.6	1
222	The role of genetic variation of human metabolism for BMI, mental traits and mental disorders. Molecular Metabolism, 2018, 12, 1-11.	6.5	19
223	07.2. BREAKTHROUGH ON ANTIPSYCHOTIC MAINTENANCE MEDICATION IN A CLINICAL COHORT. Schizophrenia Bulletin, 2018, 44, S93-S94.	4.3	0
224	Clinical risk factors for the development of tardive dyskinesia. Journal of the Neurological Sciences, 2018, 389, 21-27.	0.6	89
225	Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatrica Scandinavica, 2018, 137, 187-205.	4.5	59
226	National Patterns of Commonly Prescribed Psychotropic Medications to Young People. Journal of Child and Adolescent Psychopharmacology, 2018, 28, 158-165.	1.3	43
227	The pharmacological management of metabolic syndrome. Expert Review of Clinical Pharmacology, 2018, 11, 397-410.	3.1	80
228	Validation study of the early onset schizophrenia diagnosis in the Danish Psychiatric Central Research Register. European Child and Adolescent Psychiatry, 2018, 27, 965-975.	4.7	20
229	Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis. JAMA Psychiatry, 2018, 75, 555.	11.0	516
230	S98. THE RELATIONSHIP BETWEEN CARDIOVASCULAR RISK FACTORS AND COGNITIVE IMPAIRMENT IN PEOPLE WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS. Schizophrenia Bulletin, 2018, 44, S363-S363.	4.3	0
231	Demographic and clinical correlates of substance use disorders in first episode psychosis. Schizophrenia Research, 2018, 194, 4-12.	2.0	65
232	Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. Schizophrenia Bulletin, 2018, 44, 603-619.	4.3	137
233	Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. American Journal of Psychiatry, 2018, 175, 169-179.	7.2	46
234	A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. Schizophrenia Research, 2018, 195, 245-251.	2.0	42

#	Article	IF	CITATIONS
235	Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. Psychopharmacology, 2018, 235, 681-693.	3.1	7
236	Real-World Effectiveness of Clozapine for Borderline Personality Disorder: Results From a 2-Year Mirror-Image Study. Journal of Personality Disorders, 2018, 32, 823-837.	1.4	22
237	Comorbidity of chronic somatic diseases in patients with psychotic disorders and their influence on 4-year outcomes of integrated care treatment (ACCESS II study). Schizophrenia Research, 2018, 193, 377-383.	2.0	22
238	144 A Clinical Practice Assessment In Tardive Dyskinesia: Are Physicians Up-to-Date?. CNS Spectrums, 2018, 23, 89-90.	1.2	0
239	Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study. BMC Psychiatry, 2018, 18, 365.	2.6	22
240	Mobility for All?. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, 792-793.	0.5	0
241	What's in a Name? Moving to Neuroscience-Based Nomenclature in Pediatric Psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, 719-721.	0.5	13
242	The Role of Objectively Measured, Altered Physical Activity Patterns for Body Mass Index Change during Inpatient Treatment in Female Patients with Anorexia Nervosa. Journal of Clinical Medicine, 2018, 7, 289.	2.4	11
243	EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). European Psychiatry, 2018. 54. 124-144.	0.2	377
244	Digital Trajectories to Care in First-Episode Psychosis. Psychiatric Services, 2018, 69, 1259-1263.	2.0	31
245	Disturbing Lack of Early Intervention Studies in Bipolar Disorder—Reply. JAMA Psychiatry, 2018, 75, 1202.	11.0	0
246	Sex and body weight are major determinants of venlafaxine pharmacokinetics. International Clinical Psychopharmacology, 2018, 33, 322-329.	1.7	12
247	The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Therapeutic Advances in Psychopharmacology, 2018, 8, 303-318.	2.7	129
248	O5.1. CLOZAPINE AND LONG-TERM MORTALITY RISK IN PATIENTS WITH SCHIZOPHRENIA: PRELIMINARY RESULTS FROM A META-ANALYSIS. Schizophrenia Bulletin, 2018, 44, S86-S86.	4.3	5
249	Tardive dyskinesia risk with first―and secondâ€generation antipsychotics in comparative randomized controlled trials: a metaâ€analysis. World Psychiatry, 2018, 17, 330-340.	10.4	117
250	Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Design, Development and Therapy, 2018, Volume 12, 1215-1238.	4.3	51
251	S46. THE VALIDITY AND SENSITIVITY OF PANSS-6 IN TREATMENT-RESISTANT SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S341-S342.	4.3	0
252	Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations. Journal of Clinical Psychopharmacology, 2018, 38, 570-576.	1.4	17

#	Article	IF	CITATIONS
253	What is the riskâ€benefit ratio of longâ€term antipsychotic treatment in people with schizophrenia?. World Psychiatry, 2018, 17, 149-160.	10.4	188
254	S27. RELIABILITY OF SCHIZOPHRENIA DIAGNOSES IN CHILDREN AND ADOLESCENTS IN DENMARK. Schizophrenia Bulletin, 2018, 44, S333-S333.	4.3	0
255	ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. Journal of Psychiatric Research, 2018, 105, 23-32.	3.1	71
256	Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1463-1474.	2.2	26
257	Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia. Evidence-Based Mental Health, 2018, 21, e11-e11.	4.5	0
258	The role of meta-analyses and umbrella reviews in assessing the harms of psychotropic medications: beyond qualitative synthesis. Epidemiology and Psychiatric Sciences, 2018, 27, 537-542.	3.9	31
259	Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1475-1492.	2.2	21
260	Systematic review and guide to management of core and psychiatric symptoms in youth with autism. Acta Psychiatrica Scandinavica, 2018, 138, 379-400.	4.5	37
261	A systematic meta-analysis of the association of Neuregulin 1 (NRG1), d-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia. Journal of Neural Transmission, 2018, 125, 89-102.	2.8	21
262	Long-Acting Injectable Antipsychotics. Journal of Clinical Psychiatry, 2018, 79, AL17017WC1C.	2.2	3
263	Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis. Journal of Clinical Psychiatry, 2018, 79, 16-23.	2.2	56
264	Insomnia in Adults With Chronic Hepatitis B, Liver Failure, and Cirrhosis: A Case-Control Study. Perspectives in Psychiatric Care, 2017, 53, 67-72.	1.9	9
265	Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Review of Neurotherapeutics, 2017, 17, 593-609.	2.8	65
266	Attitudes towards and rationale for antipsychotic polypharmacy among psychiatrists in Nigeria: Characteristics associated with high reported antipsychotic polypharmacy. Psychiatry Research, 2017, 248, 134-139.	3.3	8
267	Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. Ageing Research Reviews, 2017, 35, 63-73.	10.9	182
268	Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, metaâ€analysis and metaâ€regression analysis. World Psychiatry, 2017, 16, 77-89.	10.4	156
269	Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings. Evidence-Based Mental Health, 2017, 20, e6-e6.	4.5	5
270	Pain perception in Parkinson's disease: A systematic review and meta-analysis of experimental studies. Ageing Research Reviews, 2017, 35, 74-86.	10.9	35

#	Article	IF	CITATIONS
271	Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectrums, 2017, 22, 415-426.	1.2	59
272	Impairment in Social Functioning differentiates youth meeting Ultra-High Risk for psychosis criteria from other mental health help-seekers: A validation of the Italian version of the Global Functioning: Social and Global Functioning: Role scales. Psychiatry Research, 2017, 253, 296-302.	3.3	13
273	Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a largeâ€scale metaâ€analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry, 2017, 16, 163-180.	10.4	1,082
274	A Severity-Based Clinical Staging Model for the Psychosis Prodrome: Longitudinal Findings From the New York Recognition and Prevention Program. Schizophrenia Bulletin, 2017, 43, 64-74.	4.3	54
275	Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia. JAMA Psychiatry, 2017, 74, 675.	11.0	153
276	ï‰-3 Polyunsaturated Fatty Acids to Prevent Psychosis. JAMA Psychiatry, 2017, 74, 11.	11.0	12
277	Analgesic Effects of Alcohol: A Systematic Review and Meta-Analysis of Controlled Experimental Studies in Healthy Participants. Journal of Pain, 2017, 18, 499-510.	1.4	119
278	Frequency and correlates of anticholinergic use among patients with schizophrenia in Denmark: A Nation-wide pharmacoepidemiological study. Psychiatry Research, 2017, 255, 198-203.	3.3	9
279	Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder. JAMA Psychiatry, 2017, 74, 719.	11.0	135
280	Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. Lancet Psychiatry,the, 2017, 4, 605-618.	7.4	40
281	Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria. Therapeutic Advances in Psychopharmacology, 2017, 7, 1-14.	2.7	20
282	Psychological well-being and mental health recovery in the NIMH RAISE early treatment program. Schizophrenia Research, 2017, 185, 167-172.	2.0	29
283	Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain—Reply. JAMA Psychiatry, 2017, 74, 1173.	11.0	5
284	The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research. Bipolar Disorders, 2017, 19, 524-543.	1.9	152
285	Catecholâ€ <i>O</i> â€Methyltransferase (COMT) Val158Met Polymorphism and Eating Disorders: Data From a New Biobank and Metaâ€Analysis of Previously Published Studies. European Eating Disorders Review, 2017, 25, 524-532.	4.1	6
286	Polypharmacy in Youth Treated With Antipsychotics: Do Antidepressants or Stimulants Add to the Risk for Type 2 Diabetes?. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, 634-635.	0.5	4
287	Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, 784-792.	0.5	21
288	A new class of VMAT-2 inhibitors for tardive dyskinesia. Lancet Psychiatry,the, 2017, 4, 574-575.	7.4	3

#	Article	IF	CITATIONS
289	Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of DAO, DAOA, and NRG1 Variants with Negative Symptoms and Cognitive Deficits. Frontiers in Psychiatry, 2017, 8, 292.	2.6	16
290	Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Therapeutics and Clinical Risk Management, 2017, Volume 13, 757-777.	2.0	286
291	Leptin and Physical Activity in Adult Patients with Anorexia Nervosa: Failure to Demonstrate a Simple Linear Association. Nutrients, 2017, 9, 1210.	4.1	14
292	Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring. Journal of Clinical Psychiatry, 2017, 78, e933-e939.	2.2	38
293	Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis. Journal of Clinical Psychiatry, 2017, 78, e1035-e1046.	2.2	36
294	Differential Risk of Increasing Psychotropic Polypharmacy Use in Children Diagnosed With ADHD as Preschoolers. Journal of Clinical Psychiatry, 2017, 78, e744-e781.	2.2	21
295	Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine. Journal of Clinical Psychiatry, 2017, 78, e1158-e1166.	2.2	6
296	Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use. Journal of Clinical Psychiatry, 2017, 78, e264-e278.	2.2	179
297	Technology-Assisted Parent Training Programs for Children and Adolescents With Disruptive Behaviors. Journal of Clinical Psychiatry, 2017, 78, e957-e969.	2.2	45
298	The Effects of Valbenazine in Participants with Tardive Dyskinesia. Journal of Clinical Psychiatry, 2017, 78, 1344-1350.	2.2	67
299	Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. Journal of Clinical Psychiatry, 2017, 78, 1136-1147.	2.2	58
300	Epidemiology and Prevention of Tardive Dyskinesia. Journal of Clinical Psychiatry, 2017, 78, e1426.	2.2	8
301	Extent, Time Course, and Moderators of Antipsychotic Treatment in Youth With Mood Disorders. Journal of Clinical Psychiatry, 2017, 78, 347-357.	2.2	4
302	Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. Psychopharmacology Bulletin, 2017, 47, 53-60.	0.0	16
303	Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. Psychopharmacology Bulletin, 2017, 47, 69-76.	0.0	14
304	Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and Other Assessments Based on the Simplified Negative and Positive Symptoms Interview (SNAPSI). Innovations in Clinical Neuroscience, 2017, 14, 68-72.	0.1	12
305	The association between smoking prevalence and eating disorders: a systematic review and meta-analysis. Addiction, 2016, 111, 1914-1922.	3.3	65
306	Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study. CNS Drugs, 2016, 30, 997-1006.	5.9	12

#	Article	IF	CITATIONS
307	Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis. Psychoneuroendocrinology, 2016, 72, 1-10.	2.7	31
308	Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychological Medicine, 2016, 46, 623-635.	4.5	108
309	Bone mineral density, osteoporosis, and fractures among people with eating disorders: a systematic review and metaâ€analysis. Acta Psychiatrica Scandinavica, 2016, 133, 341-351.	4.5	94
310	Digital Parent Training for Children with Disruptive Behaviors: Systematic Review and Meta-Analysis of Randomized Trials. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 740-749.	1.3	88
311	Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research, 2016, 174, 93-98.	2.0	49
312	Cognitive functioning in individuals at ultra-high risk for psychosis, first-degree relatives of patients with psychosis and patients with first-episode schizophrenia. Schizophrenia Research, 2016, 174, 71-76.	2.0	47
313	Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2016, 42, 1418-1437.	4.3	149
314	Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia. Epidemiology and Psychiatric Sciences, 2016, 25, 9-17.	3.9	19
315	Adolescents and adults at clinical high-risk for psychosis: age-related differences in attenuated positive symptoms syndrome prevalence and entanglement with basic symptoms. Psychological Medicine, 2016, 46, 1069-1078.	4.5	23
316	The Bipolar Prodrome: Meta-Analysis of Symptom Prevalence Prior to Initial or Recurrent Mood Episodes. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 543-555.	0.5	129
317	Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies. Schizophrenia Research, 2016, 174, 82-92.	2.0	44
318	ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert Review of Neurotherapeutics, 2016, 16, 601-614.	2.8	40
319	Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A Meta-Analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 456-468.e4.	0.5	57
320	Single-dose infusion ketamine and non-ketamine <i>N</i> -methyl- <scp>d</scp> -aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychological Medicine, 2016, 46, 1459-1472.	4.5	292
321	Clinical Characteristics and Predictors of Outcome of Schizophrenia-Spectrum Psychosis in Children and Adolescents: A Systematic Review. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 410-427.	1.3	104
322	Premature Mortality and Schizophrenia—The Need to Heal Right From the Start. JAMA Psychiatry, 2016, 73, 535.	11.0	7
323	Efficacy and safety of adjunctive topiramate for schizophrenia: a metaâ€analysis of randomized controlled trials. Acta Psychiatrica Scandinavica, 2016, 134, 385-398.	4.5	51
324	Is Pain Perception Altered in People With Depression? A Systematic Review and Meta-Analysis of Experimental Pain Research. Journal of Pain, 2016, 17, 1257-1272.	1.4	114

#	Article	IF	CITATIONS
325	Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophrenia Research, 2016, 176, 220-230.	2.0	97
326	Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale metaâ€analysis. World Psychiatry, 2016, 15, 166-174.	10.4	487
327	Prevalence of aggression in hospitalized patients with schizophrenia in <scp>C</scp> hina: A metaâ€analysis. Asia-Pacific Psychiatry, 2016, 8, 60-69.	2.2	58
328	Vitamin K antagonists' use and fracture risk: results from a systematic review and meta-analysis: reply. Journal of Thrombosis and Haemostasis, 2016, 14, 221-223.	3.8	1
329	Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia. CNS Spectrums, 2016, 21, 466-477.	1.2	14
330	Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries. BMC Medicine, 2016, 14, 189.	5.5	119
331	Health Technology Intervention After Hospitalization for Schizophrenia: Service Utilization and User Satisfaction. Psychiatric Services, 2016, 67, 1035-1038.	2.0	23
332	Duration of attenuated positive and negative symptoms in individuals at clinical high risk: Associations with risk of conversion to psychosis and functional outcome. Journal of Psychiatric Research, 2016, 81, 95-101.	3.1	70
333	Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CNS Spectrums, 2016, 21, 393-402.	1.2	28
334	Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 458-470.	1.3	20
335	Adaptation of a peer based online emotional support program as an adjunct to treatment for people with schizophrenia-spectrum disorders. Internet Interventions, 2016, 4, 35-42.	2.7	24
336	Self-Reported and Interviewer-Rated Oral Health in Patients With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. Perspectives in Psychiatric Care, 2016, 52, 4-11.	1.9	16
337	Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics. JAMA Psychiatry, 2016, 73, 247.	11.0	189
338	Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. Journal of Affective Disorders, 2016, 197, 268-280.	4.1	16
339	Smoking in male patients with schizophrenia in China: A meta-analysis. Drug and Alcohol Dependence, 2016, 162, 146-153.	3.2	36
340	Worldwide Differences in Regulations of Clozapine Use. CNS Drugs, 2016, 30, 149-161.	5.9	139
341	The Role of Clozapine in Treatment-Resistant Schizophrenia. JAMA Psychiatry, 2016, 73, 187.	11.0	72
342	Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opinion on Pharmacotherapy, 2016, 17, 921-936.	1.8	26

#	Article	IF	CITATIONS
343	Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opinion on Drug Safety, 2016, 15, 591-612.	2.4	29
344	Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. European Child and Adolescent Psychiatry, 2016, 25, 1091-1102.	4.7	26
345	Poor Sleep Is Related to Lower Emotional Competence Among Adolescents. Behavioral Sleep Medicine, 2016, 14, 602-614.	2.1	68
346	Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. American Journal of Psychiatry, 2016, 173, 362-372.	7.2	601
347	The Use of Long-Acting Injectable Antipsychotics in Schizophrenia. Journal of Clinical Psychiatry, 2016, 77, 1-24.	2.2	267
348	Low Hemoglobin Levels and Risk of Developing Depression in the Elderly. Journal of Clinical Psychiatry, 2016, 77, e1549-e1556.	2.2	22
349	Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders. Journal of Clinical Psychiatry, 2016, 77, e746-e756.	2.2	33
350	Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review. Shanghai Archives of Psychiatry, 2016, 28, 241-252.	0.7	4
351	Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry, 2015, 14, 56-63.	10.4	82
352	Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry, 2015, 14, 119-136.	10.4	581
353	Schizophrenia. Nature Reviews Disease Primers, 2015, 1, 15067.	30.5	724
354	The impact of psychosis on the course of cognition: a prospective, nested case-control study in individuals at clinical high-risk for psychosis. Psychological Medicine, 2015, 45, 3341-3354.	4.5	35
355	Decreased pain sensitivity among people with schizophrenia. Pain, 2015, 156, 2121-2131.	4.2	95
356	Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatrica Scandinavica, 2015, 132, 97-108.	4.5	216
357	Vitamin K antagonists' use and fracture risk: results from a systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2015, 13, 1665-1675.	3.8	43
358	Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. BMC Psychiatry, 2015, 15, 271.	2.6	13
359	Delayed identification and diagnosis of Huntington's disease due to psychiatric symptoms. International Journal of Mental Health Systems, 2015, 9, 33.	2.7	9
360	Inverse relationship between body mass index and mortality in older nursing home residents: a metaâ€analysis of 19,538 elderly subjects. Obesity Reviews, 2015, 16, 1001-1015.	6.5	138

#	Article	IF	CITATIONS
361	Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia. International Clinical Psychopharmacology, 2015, 30, 272-281.	1.7	25
362	Perfectionism related to self-reported insomnia severity, but not when controlled for stress and emotion regulation. Neuropsychiatric Disease and Treatment, 2015, 11, 263.	2.2	45
363	Clinical characteristics and influence of childhood trauma on the prodrome of bipolar disorder. Revista Brasileira De Psiquiatria, 2015, 37, 280-288.	1.7	19
364	Use of electroconvulsive therapy for Asian patients with schizophrenia (2001–2009): Trends and correlates. Psychiatry and Clinical Neurosciences, 2015, 69, 489-496.	1.8	30
365	Psychosis Prevention: A Modified Clinical High Risk Perspective From the Recognition and Prevention (RAP) Program. American Journal of Psychiatry, 2015, 172, 986-994.	7.2	128
366	Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose–response study. Psychoneuroendocrinology, 2015, 58, 130-140.	2.7	52
367	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. American Journal of Psychiatry, 2015, 172, 617-629.	7.2	150
368	Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and metaâ€analysis. World Psychiatry, 2015, 14, 339-347.	10.4	858
369	Temperament and prodromal symptoms prior to first manic/hypomanic episodes: Results from a pilot study. Journal of Affective Disorders, 2015, 173, 39-44.	4.1	21
370	A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychological Medicine, 2015, 45, 299-317.	4.5	105
371	Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 718-727.e3.	0.5	32
372	Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. European Neuropsychopharmacology, 2015, 25, 1513-1531.	0.7	56
373	Importando la Escala de SÃntomas Prodrómicos Bipolares-Prospectiva Completa Psiquiatria Biologica, 2015, 22, 30-31.	0.1	0
374	Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study. European Neuropsychopharmacology, 2015, 25, 1669-1676.	0.7	27
375	Glutamatergic agents for schizophrenia: current evidence and perspectives. Expert Review of Clinical Pharmacology, 2015, 8, 335-352.	3.1	29
376	Antipsychotic Use in Youth Without Psychosis. JAMA Psychiatry, 2015, 72, 859.	11.0	32
377	Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis. Expert Opinion on Drug Safety, 2015, 14, 1181-1199.	2.4	19
378	A functional polymorphism in the interleukin-1beta and severity of nicotine dependence in male schizophrenia: A case-control study. Journal of Psychiatric Research, 2015, 64, 51-58.	3.1	6

#	Article	IF	CITATIONS
379	Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial. American Journal of Psychiatry, 2015, 172, 870-880.	7.2	158
380	Suicidality and hospitalization as cause and outcome of pediatric psychiatric emergency room visits. European Child and Adolescent Psychiatry, 2015, 24, 797-814.	4.7	20
381	Child and Adolescent Psychiatrists' Reported Monitoring Behaviors for Second-Generation Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 351-361.	1.3	35
382	Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: Findings of the third national survey on use of psychotropic medications in China. Australian and New Zealand Journal of Psychiatry, 2015, 49, 129-136.	2.3	40
383	Ambiguous findings concerning potential advantages of depot antipsychotics. Current Opinion in Psychiatry, 2015, 28, 216-221.	6.3	47
384	Duration of Untreated Psychosis in Community Treatment Settings in the United States. Psychiatric Services, 2015, 66, 753-756.	2.0	100
385	Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 535-547.	1.3	8
386	Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. European Child and Adolescent Psychiatry, 2015, 24, 1485-1496.	4.7	18
387	Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis. Expert Opinion on Drug Safety, 2015, 14, 1587-1608.	2.4	19
388	A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Schizophrenia Bulletin, 2015, 41, 1227-1236.	4.3	100
389	Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002–2012). Schizophrenia Research, 2015, 168, 523-529.	2.0	17
390	Lack of cardinal symptoms of meningitis in a hospitalized patient with chronic schizophrenia: lessons to be learned. General Hospital Psychiatry, 2015, 37, 621.e3-621.e4.	2.4	2
391	Do antipsychotics increase diabetes risk in children and adolescents?. Expert Opinion on Drug Safety, 2015, 14, 219-241.	2.4	29
392	Corrected QT Changes During Antipsychotic Treatment ofÂChildren and Adolescents: A Systematic Review and Meta-Analysis of Clinical Trials. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 25-36.	0.5	62
393	Prescription Practices in the Treatment of First-Episode Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study. American Journal of Psychiatry, 2015, 172, 237-248.	7.2	80
394	Could the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR) be used in depressed schizophrenia patients?. Journal of Affective Disorders, 2015, 172, 191-194.	4.1	9
395	Inflammatory cytokines and anorexia nervosa: A meta-analysis of cross-sectional and longitudinal studies. Psychoneuroendocrinology, 2015, 51, 237-252.	2.7	164
396	Comparative Effectiveness of Risperidone Long-Acting Injectable vs First-Generation Antipsychotic Long-Acting Injectables in Schizophrenia: Results From a Nationwide, Retrospective Inception Cohort Study. Schizophrenia Bulletin, 2015, 41, 627-636.	4.3	44

#	Article	IF	CITATIONS
397	Frequency and Correlates of DSM-5 Attenuated Psychosis Syndrome in a Sample of Adolescent Inpatients With Nonpsychotic Psychiatric Disorders. Journal of Clinical Psychiatry, 2015, 76, e1449-e1458.	2.2	20
398	Frequency and Correlates of Distant Visual Impairment in Patients with Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. East Asian Archives of Psychiatry, 2015, 25, 115-21.	0.4	5
399	Schizophrenia relapse after stopping olanzapine treatment during pregnancy: a case report. Therapeutics and Clinical Risk Management, 2014, 10, 901.	2.0	11
400	Child and Adolescent Psychiatrists' Attitudes and Practices Prescribing Second Generation Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2014, 24, 90-93.	1.3	26
401	Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial. World Journal of Biological Psychiatry, 2014, 15, 229-241.	2.6	18
402	Adherence to Guidelines for Glucose Assessment in Starting Second-Generation Antipsychotics. Pediatrics, 2014, 134, e1308-e1314.	2.1	36
403	The Bipolar Prodrome Symptom Interview and Scale–Prospective (<scp>BPSS</scp> â€P): description and validation in a psychiatric sample and healthy controls. Bipolar Disorders, 2014, 16, 505-522.	1.9	77
404	Frequency of Hyperprolactinemia and Its Associations With Demographic and Clinical Characteristics and Antipsychotic Medications in Psychiatric Inpatients in China. Perspectives in Psychiatric Care, 2014, 50, 257-263.	1.9	10
405	Psychotherapeutic interventions in individuals at risk of developing bipolar disorder: a systematic review. Microbial Biotechnology, 2014, 8, 3-11.	1.7	29
406	Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001–2009). International Journal of Geriatric Psychiatry, 2014, 29, 359-366.	2.7	19
407	The prevalence and moderators of clinical pain in people with schizophrenia: A systematic review and large scale meta-analysis. Schizophrenia Research, 2014, 160, 1-8.	2.0	70
408	National Trends in the Mental Health Care of Children, Adolescents, and Adults by Office-Based Physicians. JAMA Psychiatry, 2014, 71, 81.	11.0	368
409	Quetiapine versus aripiprazole in children and adolescents with psychosis - protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial. BMC Psychiatry, 2014, 14, 199.	2.6	10
410	Critical Issues on the Use of Network Meta-analysis in Psychiatry. Harvard Review of Psychiatry, 2014, 22, 367-372.	2.1	19
411	Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders. JAMA Psychiatry, 2014, 71, 1350.	11.0	318
412	Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectrums, 2014, 19, 35-53.	1.2	132
413	Efficacy of Pharmacologic and Psychotherapeutic Interventions in Psychiatry. JAMA Psychiatry, 2014, 71, 624.	11.0	6
414	Characteristics, symptomatology and naturalistic treatment in individuals at-risk for bipolar disorders: Baseline results in the first 180 help-seeking individuals assessed at the dresden high-risk project. Journal of Affective Disorders, 2014, 152-154, 427-433.	4.1	23

#	Article	IF	CITATIONS
415	Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials. Schizophrenia Bulletin, 2014, 40, 192-213.	4.3	332
416	Prevalence of Nurses' Smoking Habits in Psychiatric and General Hospitals in China. Archives of Psychiatric Nursing, 2014, 28, 119-122.	1.4	12
417	Antidepressants for cognitive impairment in schizophrenia — A systematic review and meta-analysis. Schizophrenia Research, 2014, 159, 385-394.	2.0	48
418	Second-Generation Antipsychotic Use in Children and Adolescents: A Six-Month Prospective Cohort Study in Drug-NaÃ ⁻ ve Patients. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 1179-1190.e4.	0.5	76
419	Markers of inflammation in schizophrenia: association vs. causation. World Psychiatry, 2014, 13, 189-192.	10.4	54
420	Emerging drugs for schizophrenia: an update. Expert Opinion on Emerging Drugs, 2014, 19, 511-531.	2.4	44
421	Predicting and preventing bipolar disorder: the need to fundamentally advance the strategic approach. Bipolar Disorders, 2014, 16, 451-454.	1.9	7
422	SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics. SpringerPlus, 2014, 3, 187.	1.2	10
423	BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis. Schizophrenia Research, 2014, 152, 365-372.	2.0	20
424	Early specific cognitive-behavioural psychotherapy in subjects at high risk for bipolar disorders: study protocol for a randomised controlled trial. Trials, 2014, 15, 161.	1.6	25
425	Risk of Diabetes in Children and Adolescents Exposed to Antipsychotics: A Nationwide 12-Year Case-Control Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 971-979.e6.	0.5	22
426	Efficacy and Safety of Atomoxetine in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Results From a Comprehensive Meta-Analysis and Metaregression. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 174-187.	0.5	131
427	Alpha-2 Agonists for Attention-Deficit/Hyperactivity Disorder in Youth: A Systematic Review and Meta-Analysis of Monotherapy and Add-On Trials to Stimulant Therapy. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 153-173.	0.5	132
428	Frequency of Involuntary Admissions and Its Associations With Demographic and Clinical Characteristics in China. Archives of Psychiatric Nursing, 2014, 28, 272-276.	1.4	26
429	Sudden unexpected death in schizophrenia: Autopsy findings in psychiatric inpatients. Schizophrenia Research, 2014, 155, 72-76.	2.0	68
430	Type and duration of subsyndromal symptoms in youth with bipolar I disorder prior to their first manic episode. Bipolar Disorders, 2014, 16, 478-492.	1.9	91
431	Rapid clozapine titration in treatment-refractory bipolar disorder. Journal of Affective Disorders, 2014, 166, 168-172.	4.1	48
432	Symptomatic and functional remission of subjects at clinical high risk for psychosis: A 2-year naturalistic observational study. Schizophrenia Research, 2014, 156, 266-271.	2.0	46

#	Article	IF	CITATIONS
433	Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. International Journal of Neuropsychopharmacology, 2014, 17, 1095-1105.	2.1	45
434	Diabetes Risk Potentially Underestimated in Youth and Children Receiving Antipsychotics. JAMA Psychiatry, 2014, 71, 209.	11.0	17
435	Prioritization of Research Addressing Antipsychotics for Adolescents and Young Adults With Bipolar Disorder. Annals of Internal Medicine, 2014, 160, 492.	3.9	3
436	Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials. BMJ Open, 2014, 4, e005708.	1.9	8
437	Prospective Memory Performance in Non-Psychotic First-Degree Relatives of Patients with Schizophrenia: A Controlled Study. PLoS ONE, 2014, 9, e111562.	2.5	14
438	Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues in Clinical Neuroscience, 2014, 16, 505-524.	3.7	186
439	Recognition of Patients Who Would Benefit From LAI Antipsychotic Treatment. Journal of Clinical Psychiatry, 2014, 75, e29-e29.	2.2	10
440	The Role of the Extended Health Care Team in Successful LAI Therapy. Journal of Clinical Psychiatry, 2014, 75, e25.	2.2	4
441	Schizophrenia: Mechanism of Action of Current and Novel Treatments. Journal of Clinical Psychiatry, 2014, 75, 347-348.	2.2	14
442	National Trends in Second-Generation Antipsychotic Augmentation for Nonpsychotic Depression. Journal of Clinical Psychiatry, 2014, 75, 490-497.	2.2	34
443	Body Mass Index Identified as an Independent Predictor of Psychiatric Readmission. Journal of Clinical Psychiatry, 2014, 75, e573-e577.	2.2	37
444	Outcomes of SARS survivors in China: not only physical and psychiatric co-morbidities. East Asian Archives of Psychiatry, 2014, 24, 37-8.	0.4	24
445	Recognition of bipolar disorder type I before the first manic episode: challenges and developments. Expert Review of Neurotherapeutics, 2013, 13, 795-807.	2.8	11
446	Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs. European Neuropsychopharmacology, 2013, 23, 205-211.	0.7	10
447	Pharmacoepidemiology of Antipsychotic Use in Youth with ADHD: Trends and Clinical Implications. Current Psychiatry Reports, 2013, 15, 382.	4.5	35
448	Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and interventions. World Psychiatry, 2013, 12, 155-164.	10.4	249
449	Rational Use of Generic Psychotropic Drugs. CNS Drugs, 2013, 27, 353-365.	5.9	21
450	Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. Child and Adolescent Psychiatry and Mental Health, 2013, 7, 31.	2.5	19

#	Article	IF	CITATIONS
451	Suicidal ideation and suicide attempts in children and adolescents with bipolar disorder: a systematic review of prevalence and incidence rates, correlates, and targeted interventions. Bipolar Disorders, 2013, 15, 507-523.	1.9	129
452	Antipsychotic polypharmacy: A Japanese survey of prescribers' attitudes and rationales. Psychiatry Research, 2013, 209, 406-411.	3.3	28
453	The bipolar disorder prodrome revisited: Is there a symptomatic pattern?. Journal of Affective Disorders, 2013, 151, 551-560.	4.1	34
454	Antipsychotics for acute schizophrenia: making choices. Lancet, The, 2013, 382, 919-920.	13.7	14
455	Early Antipsychotic Response to Aripiprazole in Adolescents With Schizophrenia: Predictive Value for Clinical Outcomes. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 689-698.e3.	0.5	23
456	Aripiprazole for the treatment of pediatric bipolar I disorder: a 30â€week, randomized, placeboâ€controlled study. Bipolar Disorders, 2013, 15, 138-149.	1.9	62
457	Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone. Schizophrenia Research, 2013, 143, 358-362.	2.0	21
458	Associations Among Obesity, Acute Weight Gain, and Response to Treatment with Olanzapine in Adolescent Schizophrenia. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 522-530.	1.3	35
459	Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Molecular Psychiatry, 2013, 18, 53-66.	7.9	136
460	Adjunctive Use of Nonsteroidal Anti-inflammatory Drugs for Schizophrenia: A Meta-analytic Investigation of Randomized Controlled Trials. Schizophrenia Bulletin, 2013, 39, 1230-1241.	4.3	168
461	Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. International Journal of Neuropsychopharmacology, 2013, 16, 1205-1218.	2.1	257
462	Prediction of Functional Outcome in Individuals at Clinical High Risk for Psychosis. JAMA Psychiatry, 2013, 70, 1133.	11.0	202
463	Antipsychotic Polypharmacy in a Treatment-Refractory Schizophrenia Population Receiving Adjunctive Treatment With Electroconvulsive Therapy. Journal of ECT, 2013, 29, 271-276.	0.6	17
464	CNR1 Gene and Risk of the Metabolic Syndrome in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2013, 33, 186-192.	1.4	30
465	Treatment of adolescents with early-onset schizophrenia spectrum disorders. Current Opinion in Psychiatry, 2013, 26, 219-230.	6.3	82
466	A meta-analysis of cardio-metabolic abnormalities in drug naÃ ⁻ ve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry, 2013, 12, 240-250.	10.4	220
467	Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry, 2013, 12, 216-226.	10.4	356
468	Metabolic Syndrome and Metabolic Abnormalities in Bipolar Disorder: A Meta-Analysis of Prevalence Rates and Moderators. American Journal of Psychiatry, 2013, 170, 265-274.	7.2	336

#	Article	IF	CITATIONS
469	Prescribing of psychotropic medications to children and adolescents: <i>quo vadis</i> ?. World Psychiatry, 2013, 12, 127-128.	10.4	9
470	Early Nonresponse Determined by the Clinical Global Impressions Scale Predicts Poorer Outcomes in Youth with Schizophrenia Spectrum Disorders Naturalistically Treated with Second-Generation Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 665-675.	1.3	30
471	Frequency, Characteristics and Management of Adolescent Inpatient Aggression. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 271-281.	1.3	45
472	The Significance of At-Risk or Prodromal Symptoms for Bipolar I Disorder in Children and Adolescents. Canadian Journal of Psychiatry, 2013, 58, 22-31.	1.9	51
473	Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia. Journal of Clinical Psychiatry, 2013, 74, 957-965.	2.2	371
474	Translation and adaptation of the Bipolar Prodrome Symptom Scale-Retrospective: Patient Version to Brazilian portuguese. Trends in Psychiatry and Psychotherapy, 2013, 35, 62-75.	0.8	1
475	Pediatric Schizophrenia. , 2013, , 1-6.		0
476	The validity of the schizophrenia diagnosis in the Danish Psychiatric Central Research Register is good. Danish Medical Journal, 2013, 60, A4578.	0.5	118
477	National Trends in the Office-Based Treatment of Children, Adolescents, and Adults With Antipsychotics. Archives of General Psychiatry, 2012, 69, 1247.	12.3	312
478	The Field of Schizophrenia: Strengths, Weaknesses, Opportunities, and Threats. Schizophrenia Bulletin, 2012, 38, 1-4.	4.3	6
479	Osteoporosis and fracture risk in people with schizophrenia. Current Opinion in Psychiatry, 2012, 25, 415-429.	6.3	91
480	Predictors of Clozapine Response in Patients With Treatment-Refractory Schizophrenia. Journal of Clinical Psychopharmacology, 2012, 32, 678-683.	1.4	75
481	Effectiveness of a Cognitive Behavioral Weight Management Intervention in Obese Patients With Psychotic Disorders Compared to Patients With Nonpsychotic Disorders or No Psychiatric Disorders. Journal of Clinical Psychopharmacology, 2012, 32, 458-464.	1.4	14
482	Differences in Body Mass Index <i>z</i> -Scores and Weight Status in a Dutch Pediatric Psychiatric Population With and Without Use of Second-Generation Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 166-173.	1.3	18
483	Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychological Medicine, 2012, 42, 125-147.	4.5	278
484	Ask the Expert: Schizophrenia. Focus (American Psychiatric Publishing), 2012, 10, 154-156.	0.8	0
485	Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nature Reviews Endocrinology, 2012, 8, 114-126.	9.6	832
486	Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug–Induced Weight Gain. Archives of General Psychiatry, 2012, 69, 904.	12.3	165

#	Article	IF	CITATIONS
487	Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder. CNS Drugs, 2012, 26, 733-759.	5.9	136
488	Safety and tolerability of antipsychotic polypharmacy. Expert Opinion on Drug Safety, 2012, 11, 527-542.	2.4	163
489	Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. Schizophrenia Research, 2012, 140, 159-168.	2.0	161
490	Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophrenia Research, 2012, 138, 18-28.	2.0	255
491	Antipsychotic Polypharmacy. Psychiatric Clinics of North America, 2012, 35, 661-681.	1.3	93
492	Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. Frontiers in Psychiatry, 2012, 3, 62.	2.6	25
493	Treatment of Maladaptive Aggression in Youth: CERT Guidelines II. Treatments and Ongoing Management. Pediatrics, 2012, 129, e1577-e1586.	2.1	117
494	Risk constellations prior to the development of bipolar disorders: Rationale of a new risk assessment tool. Journal of Affective Disorders, 2012, 136, 1000-1010.	4.1	90
495	Antipsychotic Drug Administration Does Not Correlate with Prolonged Rate-Corrected QT Interval in Children and Adolescents: Results from a Nested Case–Control Study. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 365-368.	1.3	28
496	Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups. European Psychiatry, 2011, 26, 3-16.	0.2	19
497	Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 517-535.	1.3	221
498	Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior. Schizophrenia Research, 2011, 131, 58-62.	2.0	78
499	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry, 2011, 10, 138-151.	10.4	631
500	Antipsychotic drugs and obesity. Trends in Molecular Medicine, 2011, 17, 97-107.	6.7	256
501	Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. British Journal of Psychiatry, 2011, 199, 99-105.	2.8	169
502	Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry, 2011, 26, 144-158.	0.2	302
503	Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. European Neuropsychopharmacology, 2011, 21, 621-645.	0.7	168
504	Incidence of Tardive Dyskinesia with Risperidone or Olanzapine in the Elderly: Results from a 2-Year, Prospective Study in Antipsychotic-NaÃ ⁻ ve Patients. Neuropsychopharmacology, 2011, 36, 1738-1746.	5.4	45

#	Article	IF	CITATIONS
505	Quantifying Clinical Relevance in the Treatment of Schizophrenia. Clinical Therapeutics, 2011, 33, B16-B39.	2.5	94
506	Obesity and coronary risk in patients treated with second-generation antipsychotics. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 417-423.	3.2	29
507	Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder. Expert Opinion on Pharmacotherapy, 2011, 12, 2245-2263.	1.8	0
508	Switching among Antipsychotics in Everyday Clinical Practice: Focus on Ziprasidone. Postgraduate Medicine, 2011, 123, 135-159.	2.0	11
509	Impact of Neurocognition on Social and Role Functioning in Individuals at Clinical High Risk for Psychosis. American Journal of Psychiatry, 2011, 168, 806-813.	7.2	164
510	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry, 2011, 10, 52-77.	10.4	1,767
511	Experts' Recommendations for Treating Maladaptive Aggression in Youth. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 505-515.	1.3	23
512	Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues in Clinical Neuroscience, 2011, 13, 155-172.	3.7	38
513	What Are We Looking for in New Antipsychotics?. Journal of Clinical Psychiatry, 2011, 72, 9-13.	2.2	16
514	QT Interval Duration and Dispersion in Children and Adolescents Treated With Ziprasidone. Journal of Clinical Psychiatry, 2011, 72, 854-860.	2.2	24
515	Sudden Deaths in Psychiatric Patients. Journal of Clinical Psychiatry, 2011, 72, 936-941.	2.2	60
516	Mid-Term and Long-Term Efficacy and Effectiveness of Antipsychotic Medications for Schizophrenia. Journal of Clinical Psychiatry, 2011, 72, 1616-1627.	2.2	43
517	Developments in Pediatric Psychopharmacology. Journal of Clinical Psychiatry, 2011, 72, 655-670.	2.2	109
518	Findings of a U.S. National Cardiometabolic Screening Program Among 10,084 Psychiatric Outpatients. Psychiatric Services, 2010, 61, 892-898.	2.0	87
519	Switching and Combining Antipsychotics. CNS Spectrums, 2010, 15, 8-11.	1.2	7
520	Research in people with psychosis risk syndrome: a review of the current evidence and future directions. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2010, 51, 390-431.	5.2	167
521	10‥ear trends in the treatment and outcomes of patients with firstâ€episode schizophrenia. Acta Psychiatrica Scandinavica, 2010, 122, 356-366.	4.5	69
522	Antipsychoticâ€associated all ause and cardiac mortality: what should we worry about and how should the risk be assessed?. Acta Psychiatrica Scandinavica, 2010, 122, 341-344.	4.5	20

#	Article	IF	CITATIONS
523	Evidence-based flying taking off: maximising the effectiveness of a novel airline user decision-making tool. International Journal of Clinical Practice, 2010, 64, 1836-1837.	1.7	1
524	<i>Primum non nocere:</i> balancing the risks and benefits of prescribing psychotropic medications for youth with bipolar disorder. Bipolar Disorders, 2010, 12, 113-115.	1.9	14
525	Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placeboâ€controlled trials. Bipolar Disorders, 2010, 12, 116-141.	1.9	181
526	Past and Present Progress in the Pharmacologic Treatment of Schizophrenia. Journal of Clinical Psychiatry, 2010, 71, 1115-1124.	2.2	188
527	Review: most antipsychotic drugs more than double the prolactin levels in children and adolescents. Evidence-Based Mental Health, 2010, 13, 54-54.	4.5	1
528	Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-NaÃ ⁻ ve Schizophrenia Patients. Neuropsychopharmacology, 2010, 35, 1997-2004.	5.4	183
529	Comparing clinical and neurocognitive features of the schizophrenia prodrome to the bipolar prodrome. Schizophrenia Research, 2010, 123, 59-63.	2.0	56
530	From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. European Psychiatry, 2010, 25, S12-S21.	0.2	215
531	Management of physical health in patients with schizophrenia: practical recommendations. European Psychiatry, 2010, 25, S41-S45.	0.2	34
532	Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis. Neuropsychopharmacology, 2010, 35, 1520-1530.	5.4	206
533	Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophrenia Research, 2010, 117, 68-74.	2.0	99
534	Management of antipsychotic-related weight gain. Expert Review of Neurotherapeutics, 2010, 10, 1175-1200.	2.8	95
535	Pharmacologic treatment of schizophrenia. Dialogues in Clinical Neuroscience, 2010, 12, 345-357.	3.7	86
536	Understanding Schizoaffective Disorder. Journal of Clinical Psychiatry, 2010, 71, 8-13.	2.2	10
537	Symptomatic Presentation and Initial Treatment for Schizophrenia in Children and Adolescents. Journal of Clinical Psychiatry, 2010, 71, e29.	2.2	4
538	Lack of Effect of Stimulant Combination with Second-Generation Antipsychotics on Weight Gain, Metabolic Changes, Prolactin Levels, and Sedation in Youth with Clinically Relevant Aggression or Oppositionality. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 563-573.	1.3	50
539	Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. Schizophrenia Bulletin, 2009, 35, 443-457.	4.3	360
540	AACAP 2006 Research Forum—Advancing Research in Early-Onset Bipolar Disorder: Barriers and Suggestions. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 3-12.	1.3	21

#	Article	IF	CITATIONS
541	Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents. JAMA - Journal of the American Medical Association, 2009, 302, 1765.	7.4	867
542	The QTc interval and its dispersion in patients receiving two atypical antipsychotics. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 23-27.	3.2	21
543	Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. European Neuropsychopharmacology, 2009, 19, 629-635.	0.7	184
544	Frequency and Correlates of Inappropriate Pediatric Psychiatric Emergency Room Visits. Journal of Clinical Psychiatry, 2009, 70, 1164-1177.	2.2	52
545	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Adjunctive Aripiprazole for Schizophrenia or Schizoaffective Disorder Inadequately Treated With Quetiapine or Risperidone Monotherapy. Journal of Clinical Psychiatry, 2009, 70, 1348-1357.	2.2	105
546	Diagnosis and treatment in the early illness phase of bipolar disorders. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 50-54.	3.2	32
547	Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry, 2008, 8, 19.	2.6	54
548	Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with secondâ€generation antipsychotics. Bipolar Disorders, 2008, 10, 788-797.	1.9	143
549	Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. International Review of Psychiatry, 2008, 20, 195-201.	2.8	78
550	Predictors of Remission, Schizophrenia, and Bipolar Disorder in Adolescents with Brief Psychotic Disorder or Psychotic Disorder Not Otherwise Specified Considered At Very High Risk for Schizophrenia. Journal of Child and Adolescent Psychopharmacology, 2008, 18, 475-490.	1.3	50
551	Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes. Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 9-20.	0.5	274
552	Side Effects of Second-Generation Antipsychotics: The Experiences, Views and Monitoring Practices of Australian Child Psychiatrists. Australasian Psychiatry, 2008, 16, 253-262.	0.7	39
553	Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes. Focus (American Psychiatric Publishing), 2008, 6, 368-378.	0.8	6
554	Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry, 2008, 21, 151-156.	6.3	331
555	Identification of High-Risk Coronary Heart Disease Patients Receiving Atypical Antipsychotics. Journal of Clinical Psychiatry, 2008, 69, 578-583.	2.2	6
556	Antipsychotic Polypharmacy, Part 1: Shotgun Approach or Targeted Cotreatment?. Journal of Clinical Psychiatry, 2008, 69, 674-675.	2.2	19
557	Antipsychotic Polypharmacy, Part 2: Why Use 2 Antipsychotics When 1 Is Not Good Enough?. Journal of Clinical Psychiatry, 2008, 69, 860-861.	2.2	13
558	Elevated Cardiovascular Risk in Patients With Bipolar Disorder: When Does It Start and Where Does It Lead?. Journal of Clinical Psychiatry, 2008, 69, 1948-1952.	2.2	16

#	Article	IF	CITATIONS
559	Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. Journal of Clinical Psychiatry, 2008, 69 Suppl 4, 26-36.	2.2	45
560	Differentiation in the Preonset Phases of Schizophrenia and Mood Disorders: Evidence in Support of a Bipolar Mania Prodrome. Schizophrenia Bulletin, 2007, 33, 703-714.	4.3	175
561	One-Year Incidence Rates of Tardive Dyskinesia in Children and Adolescents Treated with Second-Generation Antipsychotics: A Systematic Review. Journal of Child and Adolescent Psychopharmacology, 2007, 17, 647-655.	1.3	87
562	Acute and Long-Term Adverse Effects of Antipsychotics. CNS Spectrums, 2007, 12, 10-14.	1.2	29
563	Balancing Efficacy and Safety in Treatment with Antipsychotics. CNS Spectrums, 2007, 12, 12-20.	1.2	64
564	Pharmacological Management of Bipolar Disorder in a Youth With Diabetes. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 1375-1379.	0.5	3
565	Weight Gain and Metabolic Effects of Mood Stabilizers and Antipsychotics in Pediatric Bipolar Disorder: A Systematic Review and Pooled Analysis of Short-Term Trials. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 687-700.	0.5	143
566	Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophrenia Research, 2007, 89, 91-100.	2.0	219
567	Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: Missed targets and lost opportunities. Schizophrenia Research, 2007, 92, 103-107.	2.0	17
568	First-Episode Psychosis: A Window of Opportunity for Best Practices. CNS Spectrums, 2007, 12, 1-16.	1.2	18
569	Early identification and highâ€risk strategies for bipolar disorder. Bipolar Disorders, 2007, 9, 324-338.	1.9	108
570	Can Antidepressants Be Used to Treat the Schizophrenia Prodrome?. Journal of Clinical Psychiatry, 2007, 68, 546-557.	2.2	185
571	Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescent Psychiatric Clinics of North America, 2006, 15, 177-206.	1.9	163
572	Endocrine and Metabolic Adverse Effects of Psychotropic Medications in Children and Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 771-791.	0.5	343
573	Real-Life Switching Strategies With Second-Generation Antipsychotics. Journal of Clinical Psychiatry, 2006, 67, 160-161.	2.2	31
574	Metabolic Syndrome and the Risk of Coronary Heart Disease in 367 Patients Treated With Second-Generation Antipsychotic Drugs. Journal of Clinical Psychiatry, 2006, 67, 575-583.	2.2	175
575	Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry, 2005, 5, 26.	2.6	148
576	Prospective Study of Adolescents with Subsyndromal Psychosis: Characteristics and Outcome. Journal of Child and Adolescent Psychopharmacology, 2005, 15, 418-433.	1.3	35

#	Article	IF	CITATIONS
577	Cost-Effective Screening for the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotic Medications. American Journal of Psychiatry, 2005, 162, 1217-1221.	7.2	89
578	Metabolic Side Effects of Second-Generation Antipsychotics in Children and Adolescents: A Different Story?. Journal of Clinical Psychiatry, 2005, 66, 1331-1332.	2.2	21
579	Real-Life Dosing With Second-Generation Antipsychotics. Journal of Clinical Psychiatry, 2005, 66, 1610-1611.	2.2	10
580	Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies. American Journal of Psychiatry, 2004, 161, 414-425.	7.2	653
581	A Prospective Study of Hyperprolactinemia in Children and Adolescents Treated with Atypical Antipsychotic Agents. Journal of Child and Adolescent Psychopharmacology, 2004, 14, 350-358.	1.3	60
582	Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology, 2004, 174, 477-89.	3.1	83
583	Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophrenia Research, 2004, 68, 37-48.	2.0	207
584	Early Prediction of Antipsychotic Response in Schizophrenia. American Journal of Psychiatry, 2003, 160, 2063-2065.	7.2	159
585	The Schizophrenia Prodrome Revisited: A Neurodevelopmental Perspective. Schizophrenia Bulletin, 2003, 29, 633-651.	4.3	327
586	The Assessment of "Prodromal Schizophrenia": Unresolved Issues and Future Directions. Schizophrenia Bulletin, 2003, 29, 717-728.	4.3	67
587	Relapse Prevention in Schizophrenia With New-Generation Antipsychotics: A Systematic Review and Exploratory Meta-Analysis of Randomized, Controlled Trials. American Journal of Psychiatry, 2003, 160, 1209-1222.	7.2	455
588	Treatment Models and Designs for Intervention Research During the Psychotic Prodrome. Schizophrenia Bulletin, 2003, 29, 747-756.	4.3	17
589	Unleashing the power of pooled and subgroup analyses in psychiatry. International Clinical Psychopharmacology, 0, Publish Ahead of Print, .	1.7	0